The ABHD6 Knockout Huh-7 Polyclonal Cells product contains a CRISPR/Cas9-edited polyclonal population of Huh-7 cells carrying a targeted disruption of the ABHD6 gene. This knockout model enables loss-of-function studies without single-cell cloning, preserving heterogeneous allele modifications across the population. ABHD6 encodes a monoacylglycerol lipase that terminates endocannabinoid signaling by hydrolyzing 2-arachidonoylglycerol (2-AG). The polyclonal format supports robust and efficient generation of ABHD6-deficient cellular models for functional investigations.
Huh-7 cells, derived from a human hepatocellular carcinoma of a 57-year-old Japanese male, serve as a well-established in vitro model for hepatocyte biology, drug metabolism, and hepatitis C virus research. Their epithelial morphology and retention of hepatocyte-specific functions make them particularly suitable for studying lipid metabolism, signal transduction, and oncogenic processes in a liver cancer background.
ABHD6 functions as a key enzyme in the endocannabinoid system, metabolizing 2-AG into glycerol and arachidonic acid, thereby regulating the availability of this major endocannabinoid at cannabinoid receptors CB1 and CB2. ABHD6 activity is influenced by upstream regulators such as PPAR??, SREBP-1c, and insulin, and works alongside interacting hydrolases like MAGL and FAAH. Disruption of ABHD6 is expected to elevate 2-AG levels, potentially enhancing retrograde endocannabinoid signaling and affecting downstream lipid mediators, including arachidonic acid-derived eicosanoids.
In the Huh-7 hepatocellular carcinoma context, ABHD6 knockout may alter lipid metabolic reprogramming and endocannabinoid tone, processes implicated in metabolic syndrome, insulin resistance, non-alcoholic fatty liver disease, and hepatocellular carcinoma progression. By modulating 2-AG signaling through CB1 receptors, this model provides a platform to dissect the contribution of ABHD6 to cancer cell proliferation, lipid accumulation, and inflammatory pathways within hepatocytes.
Typical applications include functional dissection of the endocannabinoid system in liver cancer, validation of ABHD6 as a therapeutic target for metabolic disorders, and high-throughput screening for selective inhibitors. Researchers can combine gene disruption with assays such as 2-AG quantification by LC-MS/MS, Western blotting for ABHD6, cell proliferation (MTT), migration (Transwell), lipid droplet staining (Oil Red O), and CB1 receptor activation readouts to characterize phenotypic consequences. For further information, please contact Ascent Research.
